Forecast Maintained Despite Biennial Price Cut

BMI is maintaining its short- and long-term forecasts for Japan's pharmaceutical market, despite the announcement of a possible 6.2% price cut to prescription drugs next year. This is because we anticipated the development - price cuts have taken place every two years for some time - and incorporated it into our proprietary Drug Expenditure Forecast Model.

To read the full article, please choose one of the following options: